Tag: Aquavit Pharmaceuticals

All

Aquavit Pharmaceuticals, Inc. has submitted to the U.S. FDA an Investigation of New Drug package for a new botulinum toxin, DTX-021.

Eye-tracking study highlights the need for holistic facial assessment in rhinoplasty.